(PCRX) Pacira BioSciences - Ratings and Ratios

Pacira BioSciences, Inc. (NASDAQ:PCRX) is a leading developer of non-opioid pain management and regenerative health solutions, addressing critical needs in postsurgical recovery and osteoarthritis treatment. The company specializes in innovative, minimally invasive therapies that reduce reliance on opioids, aligning with broader healthcare efforts to combat the opioid crisis. Its flagship product, EXPAREL, is a long-acting bupivacaine liposome injectable suspension designed to provide sustained pain relief for up to 72 hours after surgery. ZILRETTA, another key offering, is an extended-release corticosteroid for osteoarthritis of the knee, leveraging proprietary microsphere technology for prolonged symptom relief. The iovera system represents a non-pharmacological approach, utilizing cryoanalgesia to block pain signals at the nerve level, offering a novel alternative for patients seeking opioid-free solutions.

The company is also advancing a robust pipeline, including PCRX-201, a groundbreaking gene therapy platform aimed at enabling localized delivery of genetic medicines. This technology holds promise for addressing large, prevalent conditions such as osteoarthritis, potentially paving the way for disease-modifying treatments. Pacira further strengthens its portfolio through strategic partnerships, such as its agreement with Aratana Therapeutics to commercialize NOCITA, a veterinary version of its bupivacaine liposome injectable suspension. Originally incorporated in 2006 as Pacira Pharmaceuticals, Inc., the company rebranded as Pacira BioSciences, Inc. in 2019 to reflect its expanded focus on regenerative and bioscience solutions. Headquartered in Tampa, Florida, Pacira operates at the intersection of innovation and patient care, with a mission to redefine pain management and tissue repair.